Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$1.55
-$0.19(-8.12%)
At close: 4:00 PM EST
$1.55
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$0.84 - $309.12
Previous CloseN/A
Volume180.10K
Average Volume (3M)89.87K
Market Cap
$4.19M
Enterprise Value-$1.30
Total Cash (Recent Filing)$15.09M
Total Debt (Recent Filing)$7.96M
Price to Earnings (P/E)―
Beta2.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,543,751
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~116% TTM top-line rebound demonstrates meaningful commercial traction and expanding demand across PMGC’s businesses. Durable revenue growth improves the prospect of scaling fixed-cost coverage, supports future investment in R&D and integration of acquisitions, and underpins recovery potential if margins are restored.
Strengthened IP/Tech PositionAn exclusive, sublicensable patent license and linked academic research commitments materially bolster NorthStrive’s aerospace/defense IP moat. This creates durable commercialization and royalty pathways, supports product development, and aligns long-term academic collaboration with PMGC’s technology pipeline and competitive differentiation.
Targeted Acquisition & ConsolidationAcquiring A&B Aerospace and later merging subsidiaries streamlines operations and adds a business showing rising revenue and improved gross profit. This inorganic move can diversify revenue, deliver near-term accretion, and provide operational synergies that sustainably improve EBITDA contribution if integration executes as planned.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow highlights ongoing reliance on external financing to fund operations and R&D. Over a multi-month horizon this limits strategic optionality, increases dilution or debt risk if losses persist, and constrains the company’s ability to self-fund clinical programs or capex without new capital.
Very Thin Margins And Deep LossesA thin ~13% gross margin combined with extreme operating and net losses implies structural profitability challenges in the current business mix. Without sustained margin expansion or higher-margin product mix, the firm will struggle to convert revenue growth into durable profits, prolonging cash burn and financing needs.
Rising Leverage And Funding RiskMaterial increase in debt and a ~0.60 debt/equity ratio reduce financial flexibility and raise servicing obligations while the company remains loss-making. Higher leverage amplifies downside risk if operating cash flow doesn’t improve, making future financings more dilutive or costly and constraining strategic investments.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $0.84 and its highest was $309.12 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $4.19M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 4,543,751 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―
Ownership Overview
73.43%
Insiders
― Other Institutional Investors
26.20% Public Companies and
Individual Investors